Only a single claim is left standing in the latest bellwether trial over whether the bone-density drug Fosamax causes the jaws of users to deteriorate.

Southern District Judge John F. Keenan has granted summary judgment to Merck & Co. Inc. on all but one claim leading up to the start of the Sept. 7 trial in Secrest v. Merck & Co. Inc., 06 Civ. 6292.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]